CCR3 and asthma: Inhibiting CCR3 has demonstrated efficacy in reducing Th2 immune responses for treatment of severe asthma [16,17], and our group found the Th2 immune response itself to be positively associated with increased infarct volume and edema in stroke patients undergoing thrombectomy [8].